To look for effect of mometasone furoate ointment 0.1 percent between crisaborole 2 percent ointment, tofacitinib 2 percent ointment twice daily in mild to moderate atopic dermatitis.

A randomized assessor blinded triple arm pilot study to compare the efficacy of mometasone furoate 0.1 percent ointment versus crisaborole 2 percent ointment versus tofacitinib 2 percent ointment twice daily in patients with mild to moderate atopic dermatitis - nil

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/10/096319

Enrollment

Registered

2025-10-22

Start date

Unknown

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L20- Atopic dermatitis

Interventions

Intervention1: Mometasone 0.1 percent ointment: Mometasone 0.1 percent ointment twice daily topical application over lesions for 12 weeks Control Intervention1: tofacitinib 2 percent ointment: tofacit

Eligibility

Inclusion criteria

Inclusion criteria: Atopic dermatitis fulfilling Hanifin Rajka criteria

Exclusion criteria

Exclusion criteria: Current active herpes zoster, and bacterial infection, with prior oral immunosuppressants within 4 weeks, and topical steroids within 2 weeks of recruitment

Design outcomes

Primary

Measure	Time frame
proportion of patients showing 75 percent reduction in EASI score with mometasone furoate 0.1 percent ointment versus crisaborole 2 percent ointment versus tofacitinib 2 percent ointment once daily in patients of mild to moderate atopic dermatitisTimepoint: at baseline, 4 weeks, 8 weeks and 12 weeks.	—

Secondary

Measure	Time frame
assess the severity of pruritus (NRS) at baseline, 4 weeks, 8 weeks and the end (12 weeks) of therapy among three groups.Timepoint: baseline, 4, 8 and 12 weeks	—

Countries

India

Contacts

Public ContactShreya K

All India Institute of Medical Sciences, New Delhi

shreyakgowda@gmail.com8296529521

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026